Last 36 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 2837.50 | — | 115.08 | 31.91 | 678.33 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 5.37 | 3.72 | 3.10 | 4.12 | 4.86 | 2.55 | 3.48 | 2.10 | 1.96 | 1.74 | 1.91 | 1.83 | 1.33 | 2.37 | 1.68 | 1.36 | 1.78 | 2.06 | 3.92 | 4.12 | 3.69 |
| — | +46.0% | -11.0% | +95.9% | +148.4% | +46.6% | +82.2% | +15.0% | +47.2% | -26.6% | +13.5% | +34.0% | -25.5% | +14.8% | -57.0% | -66.9% | -51.7% | -72.8% | -53.5% | -55.1% | -49.0% | |
| P/B Ratio | 114.58 | — | 79.18 | 103.26 | — | — | — | — | — | — | — | — | 66.44 | 26.38 | 7.44 | 4.00 | 3.85 | 2.82 | 3.58 | 3.75 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | +1624.3% | +834.5% | +107.6% | +6.7% | — | -79.2% | -42.4% | -51.9% | — | |
| P/FCF | 56.13 | 19.44 | 26.98 | 17.93 | 20.00 | — | — | 72.00 | — | — | — | 13.19 | — | — | — | — | — | — | — | — | — |
| — | — | — | -75.1% | — | — | — | +446.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 40.33 | 46.80 | 21.48 | 16.91 | 35.09 | 30.29 | 4939.81 | 36.64 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | +54.5% | -99.6% | -53.9% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | 60.02 | — | 26.21 | 30.24 | 44.12 | 42.65 | — | 68.07 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | -55.6% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 81.7% | 86.4% | 84.0% | 77.8% | 85.2% | 79.6% | 85.5% | 84.2% | 75.0% | 78.2% | 85.3% | 76.8% | 83.0% | 80.1% | 84.0% | 81.0% | 82.3% | 81.0% | 71.6% | 77.4% | 70.8% |
| — | +8.6% | -1.7% | -7.7% | +13.7% | +1.8% | +0.2% | +9.6% | -9.7% | -2.5% | +1.6% | -5.2% | +0.9% | -1.1% | +17.3% | +4.6% | +16.2% | +30.6% | -7.9% | +47.5% | +1.1% | |
| Operating Margin | 8.5% | 5.6% | 9.5% | 19.5% | 9.0% | 6.3% | -5.1% | 2.8% | -23.8% | -17.0% | -35.1% | -22.2% | -10.2% | -42.0% | -40.0% | -45.8% | -63.2% | -74.7% | -131.7% | -222.8% | -220.7% |
| — | -10.3% | +285.3% | +599.7% | +138.1% | +136.8% | +85.3% | +112.6% | -133.7% | +59.5% | +12.4% | +51.6% | +83.9% | +43.8% | +69.6% | +79.5% | +71.4% | +74.2% | +35.5% | +17.4% | -51.7% | |
| Net Margin | 0.2% | -33.8% | 2.7% | 12.9% | 0.8% | -2.7% | -15.3% | -8.5% | -29.0% | -31.2% | -46.7% | -30.2% | -25.2% | -52.2% | -50.7% | -39.0% | -73.4% | -103.5% | -152.7% | -234.4% | -235.7% |
| — | -1153.0% | +117.5% | +251.8% | +102.9% | +91.4% | +67.2% | +71.8% | -15.0% | +40.2% | +7.9% | +22.7% | +65.7% | +49.5% | +66.8% | +83.4% | +68.8% | +66.5% | +32.0% | +23.1% | -39.2% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 4.0% | -1898.1% | 16.7% | 172.8% | — | — | — | — | — | — | — | — | -139.3% | -90.8% | -44.8% | -25.8% | -33.9% | -30.7% | -35.2% | -109.5% | -298.5% |
| — | — | — | — | — | — | — | — | — | — | — | — | -311.4% | -195.5% | -27.2% | +76.4% | +88.7% | +64.1% | +25.3% | -20.5% | -261.1% | |
| ROA | 0.2% | -7.7% | 0.6% | 2.9% | 0.2% | -0.6% | -2.9% | -1.6% | -4.8% | -4.5% | -5.8% | -4.1% | -3.7% | -6.1% | -5.1% | -4.0% | -7.0% | -8.0% | -10.5% | -23.3% | -18.4% |
| — | -1204.6% | +119.9% | +285.2% | +103.7% | +86.8% | +49.8% | +61.4% | -29.9% | +26.4% | -13.9% | -3.1% | +47.1% | +23.5% | +51.9% | +82.9% | +61.8% | +53.7% | +6.8% | -75.8% | -93.3% | |
| ROIC | 33.8% | 8.0% | — | — | 8.1% | 1.9% | -1.3% | 0.7% | -5.1% | -3.2% | -6.1% | -4.3% | -1.9% | -6.5% | -6.7% | -9.9% | -12.5% | -11.5% | -17.7% | -51.1% | -52.6% |
| — | +323.0% | — | — | +258.0% | +160.3% | +77.9% | +116.4% | -163.7% | +51.4% | +8.9% | +56.1% | +84.4% | +43.5% | +62.3% | +80.7% | +76.3% | +67.7% | -4.4% | -215.1% | -224.3% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 2.76 | — | 2.87 | 2.76 | — | — | — | — | — | — | — | — | 58.98 | 16.49 | 6.60 | 4.38 | 2.52 | 1.87 | 1.43 | 0.92 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | +2243.6% | +783.3% | +361.6% | +374.0% | — | -57.5% | -27.2% | -64.1% | — | |
| Debt / EBITDA | 1.02 | 35.27 | 3.36 | 1.91 | 3.85 | 33.64 | 5070.77 | 56.41 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | +4.8% | -99.9% | -96.6% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.19 | 1.45 | 2.12 | 2.19 | 1.93 | 1.95 | 1.72 | 1.67 | 1.79 | 2.26 | 2.37 | 1.64 | 1.82 | 1.95 | 2.03 | 2.54 | 2.17 | 2.50 | 2.67 | 1.80 | 3.34 |
| — | -25.7% | +23.4% | +31.4% | +7.8% | -13.6% | -27.5% | +1.7% | -1.5% | +15.4% | +16.6% | -35.3% | -16.4% | -21.7% | -23.9% | +40.7% | -34.9% | -38.7% | -54.4% | -66.6% | -44.8% | |
| Quick Ratio | 1.57 | 1.02 | 1.50 | 1.57 | 1.35 | 1.24 | 1.17 | 1.19 | 1.29 | 1.69 | 1.81 | 1.23 | 1.38 | 1.50 | 1.68 | 2.20 | 1.88 | 2.22 | 2.42 | 1.57 | 2.95 |
| — | -17.7% | +28.4% | +31.7% | +4.2% | -26.3% | -35.7% | -3.6% | -6.1% | +12.8% | +8.1% | -44.0% | -26.7% | -32.6% | -30.6% | +39.8% | -36.4% | -40.5% | -55.3% | -69.1% | -49.3% | |
| Interest Coverage | 0.02 | -3.48 | 1.32 | 1.55 | 1.09 | 0.74 | -0.26 | 0.34 | -1.45 | -0.79 | -1.66 | -0.94 | -0.83 | -2.14 | -1.71 | -2.04 | -4.56 | -6.69 | -8.69 | -27.28 | -13.47 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 36 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying XERS stock.
Xeris Biopharma Holdings, Inc.'s current P/E is 2837.5x. The average P/E over the last 3 quarters is 275.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Xeris Biopharma Holdings, Inc.'s current operating margin is 8.5%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Xeris Biopharma Holdings, Inc.'s business trajectory between earnings reports.